InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,473.17
(
-0.25%
)
US TECH 100
19,258.80
(
-0.77%
)
Dow Jones
39,134.76
(
0.77%
)
Brent Oil
85.02
(
0.38%
)
Bitcoin
64,984.48
(
0.03%
)
Post# of 80490
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

BTH

Send PM Follow Ignore
Followers 16
Posts 4145
Boards Moderated 1
Alias Born 06/11/2010

BTH

Re: JJM760 post# 2682

Thursday, 10/21/2010 12:19:43 PM

Thursday, October 21, 2010 12:19:43 PM

Post# of 80490
For the same reason that Novartis' everolimus trial they had an abstract on at ESMO in which they said it "didn't meet the trials endpoints" yet the trial showed substantial efficacy. A trial can show efficacy, yet still not meet the pre-determined endpoint.


I don't know what Merck's endpoint is. Neither do you.

What I do know is that it doubled the PFS, and it doubled the response rate.

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up